Cxbladder Adoption Roll-Out Advances in New Zealand

18 March 2019

CXBLADDER ADOPTION ROLL-OUT ADVANCES IN NZ
Public Healthcare provider, Hawke’s Bay District Health Board, to roll out Cxbladder tests

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) have signed an agreement with Hawke’s Bay District
Health Board (HBDHB), further extending the adoption and commercial coverage of Cxbladder for the New Zealand
population.

This latest announcement follows a succession of public healthcare providers, which have signed up within the last
six months to offer Cxbladder testing as part of urology services within their regions, including Counties Manukau,
Hauora Tairawhiti and Capital & Coast/Hutt Valley DHBs. The majority of New Zealand’s public health care
providers now provide access to Cxbladder, with its ease of use, cost effectiveness and accuracy providing multiple
benefits to patients and physicians.

Hawke’s Bay DHB, based in Hastings, covers an area along the North Island’s east coast, which includes Wairoa,
Napier, Hastings and Waipukurau, serving a population, of which one-quarter are Māori and with a higher than
average number of people aged 50 years or older.

Hawke’s Bay urologists, Kim Broome, David Mason, Leanne Shaw and urology registrar Josh Silverman are driving
the adoption of Cxbladder in the region, where patients will be able to provide a urine specimen at their local
diagnostic lab, potentially avoiding the need to travel to the urology clinic or hospital for investigation.

Mr Mason said he and the entire Hawke’s Bay urology team were delighted to have Cxbladder testing available for
patients. “It will speed up the management of patient diagnosis and provide us with greater efficiencies in
investigations for patients,” Mr Mason said.

Brent Pownall, VP Commercial and Franchise at Pacific Edge, said: “We now have strong clinical buy-in for the
accuracy, efficacy and utility of Cxbladder across the clinical pathway for haematuria and bladder cancer follow-up.

“Collectively, the New Zealand urology community is embracing the Cxbladder technology, leading to significant
changes in the way bladder cancer is diagnosed and managed, with the majority of New Zealand’s public healthcare
care providers now providing access to Cxbladder for their patient populations.

“This is another milestone for Pacific Edge in New Zealand, and one which is also being followed closely by key
decision makers in other markets.”

Cxbladder offers an easy-to-use, non-invasive method of detection of bladder cancer for patients referred by the
GP for evaluation of blood in the urine (haematuria) a key indicator of bladder cancer, through to management and
monitoring for recurrence of the disease by the urologist. Cxbladder has been shown to significantly reduce the
number of patients who will need a full urological evaluation, including many patients no longer requiring an
invasive cystoscopy procedure (a thin tube inserted via the urethra to look inside the bladder).


ENDS

18 March 2019
For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of
non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of
urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through
its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in
international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients
with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low
probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the
cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a
recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior
history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial
carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients
for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder
Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage,
Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late
stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for
further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.